Reuters shared the FDA’s announcement to postpone its advisory committee meeting to review HRA Pharma’s application for an over-the-counter birth control pill.
U.S. FDA delays panel meeting on Perrigo's OTC birth control pill
Previous
Previous
Removing the ‘prescription’ barrier
Next
Next